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Abstract 
 
Purpose: With the potential to address evaporative dry eye, a novel spray has been developed in which 
phospholipid liposomes are delivered to the tear film via the surface of the closed eyelid.  This study 
evaluated the short-term effects of liposomal spray application on the lipid and stability characteristics of 
the pre-ocular tear film in normal eyes. 
 
Methods: Twenty-two subjects (12M, 10F) aged 35.1 ± 7.1 years participated in this prospective, 
randomised, double-masked investigation in which the liposomal spray was applied to one eye, and an 
equal volume of saline spray (control) applied to the contralateral eye.  Lipid layer grade (LLG), non-
invasive tear film stability (NIBUT) and tear meniscus height (TMH) were evaluated at baseline, and at 30, 
60, 90 and 135 minutes post-application. Subjective reports of comfort were also compared. 
 
Results: Treated and control eyes were not significantly different at baseline (p>0.05). Post-application, 
LLG increased significantly, at 30 and 60 minutes, only in the treated eyes (p=0.005). NIBUT also 
increased significantly in the treated eyes only (p<0.001), at 30, 60 and 90 minutes.  TMH did not alter 
significantly (p>0.05). Comfort improved relative to baseline in 46% of treated and 18% of control eyes, 
respectively, at 30 minutes post-application.  Of those expressing a preference in comfort between the 
eyes, 68% preferred the liposomal spray. 
 
Conclusions: Consistent with subjective reports of improved comfort, statistically and clinically significant 
improvements in lipid layer thickness and tear film stability are observed in normal eyes for at least an 
hour after a single application of a phospholipid liposomal spray. 
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Introduction: 
 
The term ‘dry eye’ describes an ocular surface disorder of varying aetiology, but with common features 
including tear film hyperosmolarity and instability, visual disturbance, and symptoms of grittiness, burning 
and irritation.[1] It is a common disorder, with a reported prevalence of between 5% and 35%, depending 
on the age of the population studied and the diagnostic criteria used.[2] (DEWS epidemiology 
subcommittee) Dry eye is typically described as either aqueous-deficient or evaporative in origin, but 
these aetiologies are not mutually exclusive, and increased evaporation has been reported to be the more 
significant factor, contributing to dry eye signs and symptoms in as many as 78% of patients.[3-5] 
 
The lipid layer of the tears has long been recognised to play an important role in inhibiting tear film 
evaporation.[6] Interfometrically, individuals without a visible lipid layer, or with a non-confluent lipid layer, 
exhibit a four-fold higher rate of tear film evaporation than those with a continuous lipid layer, irrespective 
of the lipid layer thickness.[7] Arising primarily from the meibomian glands of the eyelid, the lipid layer is a 
complex structure with a thin, inner polar layer, interfacing with the aqueous phase and reducing surface 
tension, and a thicker, outer, non-polar layer which is believed to inhibit tear evaporation.[8, 9] Meibomian 
gland dysfunction results in abnormal lipid production and has been identified as one of the major causes 
of ocular discomfort and ocular surface abnormality.[10-12] 
 
Improved treatments for dry eye continue to evolve but, at the current time, artificial tear supplementation 
remains the primary therapy.  Traditionally, the focus of such therapies has been to augment tear film 
volume to compensate for aqueous insufficiency but more recently, attention has been directed towards 
creating supplements that address deficiency in the tear film lipids. In the last decade, researchers have 
reported significant reductions in tear evaporation and improvements in lipid layer thickness with topical 
lipid emulsion eye drops containing neutral oils and castor oil.[5, 13-15] 
 
In recent years, a phospholipid liposomal spray developed in Germany (Tears Again®, Optima 
Pharmazeutische GmbH) has been generating interest as a potential therapy for evaporative dry eye.  The 
spray is applied to the closed eyelids, and the liposomes migrate, via the lid margins, into the tear film.  
Improvements in symptomatology, visual acuity, eyelid margin inflammation, tear production and lid 
parallel conjunctival folds have been documented with use of the lipid spray in patients with dry eye,[16-
18] in contact lens wear[19] and following cataract surgery.[20] The observed changes are attributed to 
improvements in the lipid layer, however, to the best of our knowledge, there is no documented evidence 
of changes in the appearance of the tear film lipid layer, following application of the liposomal spray, to 
support these claims.  This study was designed to investigate the effect of a single application of the 
liposome spray on the pre-ocular tear film in a group of normal and mildly symptomatic dry eye subjects. 
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Methods 
 
The subject group comprised 22 non contact lens wearing individuals (12 males, 10 females) with a mean 
age of 33.5 ± 7.1 years (age range 24 to 46 years).  There was no history or evidence of systemic or 
ocular disease other than self-reported borderline dry eye in four subjects, according to McMonnies Dry 
Eye Questionnaire.[21] 
 
Lipid patterns and tear film stability were assessed non-invasively with the Tearscope Plus™ (Keeler Ltd, 
Berkshire, UK).  Lipid patterns were graded according to the Guillon classification,[22] based on the 
predominant pattern visible during a 60 second examination-period with unrestricted participant blinking. 
The patterns were recorded as absent, open meshwork, closed meshwork, flow, amorphous or (evenly 
distributed) coloured fringes, corresponding to increasing lipid layer thickness, and assigned a lipid layer 
grade (LLG) of 0 to 5, respectively, for the purpose of analysis. 
 
Use of the fine grid insert with the Tearscope Plus™ facilitated measurement of the non-invasive break-up 
time (NIBUT).  Subjects were instructed to blink and then to refrain from blinking while the examiner 
observed the reflected grid pattern.  NIBUT was recorded as the time between the blink and the first sign 
of a distortion or disruption in the reflected grid pattern.  If the subject blinked prior to signs of break-up, 
the measurement was repeated.  A mean of three measurements was calculated.  Tear meniscus height 
(TMH) was evaluated from calibrated, 10x magnified digital video images collected at baseline and at 
each subsequent time point with a CSO (CSOphthalmic, Florence, Italy) digital slit lamp.[23] 
 
The study was prospective, controlled, double-masked and randomised in design. LLG, NIBUT and TMH 
were evaluated for both eyes of each subject at baseline. Following a single application of the liposomal 
spray (Tears Again, currently marketed in UK as Optrex ActiMist™) to one eye and an identical volume 
(0.11 ± 0.01ml) of saline spray to the contralateral eye, from a distance of 10cm and with the aid of a 
septum to minimise the risk of inter-ocular contamination, LLG, NIBUT, TMH and subjective comfort were 
recorded at 30 minutes, 60, 90 and 135 minutes. A computer-generated randomisation schedule 
determined the application order and the eye to which each spray was applied for each participant.  An 
investigator remote to the clinical evaluations applied the sprays (investigator-masked) and subjects’ eyes 
remained closed throughout the application process to ensure participant-masking. 
 
Subjective comfort was established at each time point by asking subjects, firstly, to relate their comfort to 
baseline in each eye (more comfortable / less comfortable / no different) and, secondly, to express a 
preference for their more comfortable eye (right eye / left eye / no difference). Data collection occurred 
over a period of two days during which environmental conditions remained stable at 25.4±0.3°C and 
57.0±1.7% relative humidity.  All measurements were collected at least 2 hours after wakening to minimise 
closed eye tear film effects.[24] 
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Research was conducted in accordance with the Declaration of Helsinki, with local ethical approval from 
Aston University Ethics Committee. Each subject was required to provide informed written consent prior to 
participation.  
 
Statistical analysis 
Statistical analysis was performed with SPSS v.16.0. Normally distributed continuous data underwent 
parametric statistical analysis.  Normality was confirmed for the TMH data (Kolmogarov-Smirnoff, p>0.05), 
and for the positively skewed tear film stability (NIBUT) data following logarithmic transformation.  Ordinal 
lipid data were analysed with non-parametric tests.  A p-value of <0.05 was considered statistically 
significant. 
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Results 
 
Prior to application of the liposomal spray, there were no significant differences in lipid characteristics, 
NIBUT or TMH between the treated and control groups (Mann-Whitney U, p=0.508; Unpaired Student t, 
p=0.672 and 0.815, respectively). Mean or median pre- and post-application values for the measured 
parameters across the time points are summarised in Table 1. 
 
Post-application, significant differences in lipid layer thickness were observed across the time-points in the 
treated eyes (Friedman, p=0.005) but not in the control eyes (Friedman, p=0.121).  Post-hoc testing in the 
treated eyes confirmed significant increases in lipid thickness, relative to baseline, at the 30 and 60-minute 
time points, but not at 90 or 135 minutes. Median lipid layer thickness categories across the time points 
are shown for the treated and control eyes in Figure 1.  Significant differences in lipid patterns between 
the treated and control eyes were established at the 30, 60 and 90-minute time points (Wilcoxan, 
p=0.0016, p=0.0018, p=0.348, respectively) but not at baseline or 135 minutes (p=0.1597 and p=0.9998, 
respectively). 
 
Repeated measures ANOVA demonstrated that tear film stability (NIBUT) varied significantly across the 
measurement period in the treated eyes (p<0.001), but not in the control eyes (p=0.925). Scheffe post-hoc 
testing in the treated eyes indicated that NIBUT was significantly increased at the 30, 60 and 90 minute 
time-points (p<0.05 in all cases), but returned to baseline levels by 135 minutes post-application. Figure 2 
shows the variation in tear film stability across the measurement period in both treated and control eyes. 
Significant differences in NIBUT between treated and control eyes were established at the 30, 60 and 90-
minute time points (Paired Student t, p=0.0001, p=0.0003, p=0.018, respectively) but not at baseline or 
135 minutes (p=0.1684 and p=0.9266, respectively). 
 
TMH was not found to vary significantly across the time-points in either the treated or control eyes 
(repeated measures ANOVA, p=0.058 and p=0.080, respectively), nor between the treated and control 
eyes at any time-point (p>0.05). 
 
Comfort relative to baseline: Subjectively, improved comfort relative to baseline was noted by over 70% of 
subjects in the treated eye, maximal at the 30-minute time-point.  By 90 minutes post-application, 80% of 
subjects were unaware of a difference in comfort relative to baseline.  Approximately 18% of subjects 
reported increased comfort in the control eye, relative to baseline, across all time-points (Figure 3). 
 
Subject Preference: At 30 minutes post-application, over 50% of subjects reported superior comfort in the 
treated eye compared with the control eye (Figure 4). No difference between the treated and control eyes 
was reported by 60 minutes post-application. Approximately one quarter of subjects recorded a preference 
for saline at each time point. 
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Discussion 
 
Meibum contains a multitude of lipid species, 92% of which are neutral lipids and 8%, polar lipids.[11] The 
polar lipids consist of 70% phospholipids, the most predominant of which, comprising 38% of the 
phospholipid component, is phosphatidylcholine.  
 
Polar lipids and, in particular, phospholipids are recognised to be important components within the tear 
film for their role in surface monolayer formation, and for their surfactant properties. In order for the 
hydrophilic aqueous-mucin phase of the tear film to support a hydrophobic non-polar lipid layer on the 
surface, an interposing surfactant layer is necessary.[9, 11] The polar lipids are understood to fulfil this 
role, not only facilitating apposition of these naturally repellent layers, but also functioning as a matrix 
upon which the superficial non-polar layer can form. Deficiency of these components prevents formation of 
a stable, continuous lipid layer, which, in turn, causes increased tear evaporation rates.[7, 11] 
 
Increasing the levels of the natural meibomian lipids by warm compress treatment,[25] digital 
expression[26] or latent heat[27] can increase lipid layer thickness and tear film stability.  However, these 
techniques are time-consuming and may require considerable effort.  Artificial supplementation has the 
potential to offer a convenience that cannot be afforded by traditional methods.   
 
The commercially available liposomal spray (Tears Again®) represents a novel delivery system, in which 
the major phospholipid, phosphatidylcholine, is delivered in a stable form (liposomes) to the closed eyelid 
and from there, migrates across the eyelid margins to combine with the natural tear film. Observation of 
the tear film following application of the liposomal spray combined with fluorescein, for visualisation 
purposes, has clearly demonstrated migration of the solution from the closed eyelids into the tear film after 
only a few blinks.[16] Liposomes are microscopic spherical vesicles, which form when hydrated 
phospholipids become organised, with consistent head-tail orientation, into circular sheets.[28] The sheets 
combine to form a phospholipid bi-layer membrane, which encapsulates aqueous-soluble material within 
aqueous to create a phospholipid sphere. As the liposomes are held together by hydrophobic interactions, 
they remain stable in aqueous solvents.[18] 
 
Improvements in a number of tear film and ocular surface parameters, most significantly in the level of 
eyelid margin inflammation, have been reported with use of the liposomal spray.[16-18] This is presumed 
to be as a result of improvement of the tear lipid layer but, to date, the effect of application of the spray on 
the appearance of the lipid layer has not been described. 
 
In the current study, it was observed that application of the liposomal spray caused a significant increase 
in the thickness of the tear film lipid layer for up to 60 minutes post-application. An improved polar lipid 
layer is believed to facilitate support of a thicker non-polar layer.[9, 11] Phospholipids are fundamental 
constituents of the polar lipid layer, understood to afford vital surfactant properties.[29]  
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Inclusion of a control (saline) in the study, enabled confirmation that lipid increases were a result of the 
liposomal spray application and not from increased meibomian gland secretions resulting from forceful 
blinking.  Participant and examiner masking enabled comparison of both objective and subjective data 
following spray administration. 
 
A significant increase in tear film stability, evaluated non-invasively, was also measured up to 90 minutes 
post-application in this double-masked study.  An association between lipid layer grade and tear film 
stability has been identified previously, with thicker lipid layers associated with increased tear film stability 
and a reduced inter-blink period.[7] The increased tear film stability following application of the liposomal 
spray in the current study is consistent with the findings of previous longer-term studies, where tear break-
up time has been shown to increase significantly.[16, 18] 
 
One of the main disadvantages of artificial tear supplements is frequently quoted to be the short retention 
time, with many supplements providing symptomatic relief for only several minutes. Evidence of the 
beneficial effects of increased lipid thickness and tear film stability for periods of over an hour shows 
promise for this liposomal product. 
 
Somewhat surprisingly, given the asymptomatic nature of the vast majority of participants prior to 
involvement in the study, comfort was reported to be improved relative to baseline, in over 45% of eyes 
treated with the liposomal spray, but less than 20% of the eyes subjected to the saline spray.  This 
improved comfort has been reported in other studies of the liposomal spray, and might be further 
increased in a study of individuals symptomatic of dry eye at the outset.  Indeed, improved comfort has 
been reported in a number of other studies of the liposomal spray,[16, 18-20] although not all were 
participant masked and therefore may have been subject to bias.  Favourable feedback on the liposomal 
spray in the current study is supported by anecdotal clinical evidence suggesting that patients appreciate 
the convenience of the modality, the ease of administration compared with eye drops, and often tolerate 
the spray better than alternative supplements, especially gels, due to the absence of an adverse effect on 
vision with the spray.[30]  
 
A limitation of the current study was the absence of significant dry eye signs and symptoms in the subject 
group. A similar study in patients with evaporative dry eye associated with reduced lipid availability is 
currently underway to determine the potential for improvement of tear film quality and symptomatic relief in 
this subject group.  
 
Although the potential benefits of artificial lipid supplementation were described as early as 1990,[31] 
measurable benefits have become evident only relatively recently, with the formulation of a number of 
lipomimetic products, capable of delivering lipid components in a stable and functional form.  While 
improving the quality and increasing availability of the natural tear film lipids through traditional and 
innovative eyelid therapies should not be underestimated, the availability of artificial lipomimetic products 
with proven benefit, in drop or spray form, provides a welcome addition to the armament of the clinician 
involved in the management of dry eye. 
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Conclusions 
Significant improvements in tear film stability and lipid layer thickness can be achieved in normal eyes for 
between 60 and 90 minutes following a single application of a phospholipid liposomal spray to the closed 
eye. 
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Figure legends 
 
Figure 1: Distribution of lipid patterns at each time point for the (a) treated and (b) control eyes.  Lipid 
patterns are graded in order of thickness from absent [Abs], through open meshwork [M(o)], 
closed meshwork [M(c)], flow [F], and amorphous [Am] to evenly distributed coloured 
fringes [CF]. Asterisks (*) denote significant differences from baseline. 
 
Figure 2: Mean non-invasive break-up time (NIBUT) across all time points for the treated and control 
eyes.  Error bars show NIBUT standard deviation and asterisks (*) highlight significant 
differences in NIBUT from baseline. 
 
Figure 3: Reported comfort relative to baseline, in the treated and control eyes, at each post-
application time point. 
 
Figure 4: Subjective preference between the treated and control eyes, post-application, with regard to 
comfort across at each time point. 
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Table 1: Mean (or median) pre- and post-application values for the measured parameters across all 
time points 
 
 
  Pre-application Time post-application (minutes) 
 Eye Baseline 30 60 90 135 
Lipid grade 
median (min, max) 
T 2 (0, 4) 3 (2, 5) 3 (2, 5) 3 (0, 5) 2 (1, 4) 
C 2 (0, 4) 3 (0, 4) 2 (1, 4) 2 (0, 4) 2 (0, 4) 
NIBUT (s) 
(mean ± sd) 
T 13.1 ± 8.8 24.3 ± 14.8 22.0 ± 12.2 23.0 ± 13.7 17.6 ± 17.1 
C 15.5 ± 13.2 14.2 ± 9.0 16.6 ± 12.0 17.0 ± 11.7 15.5 ± 9.4 
TMH (mm) 
(mean ± sd) 
T 0.39 ± 0.13 0.38 ± 0.10 0.38 ± 0.11 0.35 ± 0.10 0.36 ± 0.10 
C 0.40 ± 0.12 0.37 ± 0.10 0.38 ± 0.12 0.36 ± 0.13 0.37 ± 0.12 
Comfort relative to 
baseline (% better) 
T - 45.5 40.9 22.7 26.6 
C - 18.2 22.7 18.2 20 
Comfort relative to 
baseline (% worse) 
T - 22.7 13.6 0 6.7 
C - 27.3 18.2 18.2 13.3 
Comfort T vs C eye 
(% prefer T) 
 - 
59.1 40.9 27.3 20 
Comfort T vs C eye 
(% prefer C) 
 - 
27.3 27.3 27.3 26.7 
Comfort T vs C eye 
(% equal) 
 - 
13.6 31.8 45.4 53.3 
 
Key: min = minimum, max = maximum, NIBUT = non-invasive break up time, T = treated eye, C = control eye, 
sd = standard deviation 
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